北京神州细胞生物技术集团股份公司2025年年度业绩预告

Group 1 - The company expects a net loss attributable to shareholders of the parent company for 2025, ranging from -580 million to -520 million yuan, compared to a profit of 111.95 million yuan in the previous year [1][5] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be between -563 million and -503 million yuan [2] - Research and development investment for 2025 is anticipated to be between 830 million and 870 million yuan [3] Group 2 - The previous year's total profit was 112.35 million yuan, with a net profit attributable to shareholders of the parent company at 111.95 million yuan, and a net profit after deducting non-recurring gains and losses at 474.41 million yuan [5] - The previous year's research and development investment was 936.02 million yuan [6] - Earnings per share for the previous year were 0.24 yuan [7] Group 3 - The decline in sales revenue is attributed to the ongoing healthcare cost control policies and significant price reductions of the core product, Anjia [8] - The company has increased commercialization investments, including academic promotion and sales team formation, leading to a noticeable rise in sales expenses [8] - The company continues to advance multiple product pipelines, with several projects entering critical confirmatory clinical trial phases, maintaining high levels of R&D investment, which impacts current profitability [8]